Analysts' Actions: ARIA, EA, HGSI, BBBY

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Ariad Pharmaceutical ( ARIA) was initiated with a Buy rating at UBS. $20 price target. Near-term driver of phase I/II date from AP26113, UBS said.

Bed Bath & Beyond ( BBBY) was downgraded at Canaccord Genuity from Buy to Hold. $73 price target. Company is losing market share, Canaccord said.

Bill Barrett ( BBG) was initiated with a Hold rating at Deutsche Bank. $30 price target. Company remains highly leveraged to natural gas, Deutsche said.

BioMarin ( BMRN) was initiated with a Buy rating at UBS. $43 price target. GALNS can be a $500 million product, UBS said.

Electronic Arts ( EA) was initiated with a Neutral rating at Ascendiant. $16 price target. Concerns remain around industry growth and the company's key games, Ascendiant said.

Human Genome ( HGSI) was initiated with a Neutral rating at UBS. $8 price target. Company will continue to trade on monthly IMS sales for Benlysta, UBS said.

IDT Corp. ( IDT) was upgraded to hold at TheStreet Ratings.

MAP Pharmaceuticals ( MAPP) was downgraded to sell at TheStreet Ratings.

MercadoLibre ( MELI) was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $93 price target, Goldman said.

Mattress Firm ( MFRM) was initiated with a Hold rating at Stifel Nicolaus. Valuation call, as the stock is up 132% since its IPO.

Packaging Corp. ( PKG) was upgraded at JP Morgan from Underweight to Neutral. Company continues to execute well.

AT&T ( T) was upgraded at JP Morgan to Overweight from Neutral. $33 price target. Higher tablet demand should drive ARPU growth, JP Morgan said.

United Therapeutics ( UTHR) was downgraded at Leerink Swann to Market Perform. Company is facing increased generic risk, Leerink Swann said.

Whiting Petroleum ( WLL) was initiated with a Buy rating at Brean Murray. $70 price target. Company was also placed on the Focus List. Company should deliver more consistent drilling results, Brean Murray said.

Stock Comments / EPS Changes

Apple ( AAPL) estimates, target were increased at Credit Suisse. Estimates were raised through 2013. Company is seeing higher iPhone sales, Credit Suisse said. Outperform rating and new $750 price target.

ADTRAN ( ADTN) price target was raised to $34 at Jefferies. Solid first-quarter results, Jefferies said. Hold rating.

American Express ( AXP) price target was raised at Guggenheim to $67. Digital platform should drive future growth, Guggenheim said. Buy rating.

Cree ( CREE) estimates, target were raised at Keybanc. Shares are now seen reaching $37. Estimates were also increased, as the industry cycle appears to be bottoming, Keybanc said. Buy rating.

EMC ( EMC) estimates, target were raised at Sterne Agee. Estimates were increased through 2013. Recent survey suggests that the company is gaining market share, Sterne Agee said. Buy rating and new $32 price target.

LinkedIn ( LNKD) price target was raised at Morgan Stanley to $115. Company is realizing higher sales efficiencies, Morgan Stanley said. Overweight rating.

Qualcomm ( QCOM) estimates, price target were increased at Credit Suisse. Estimates were boosted through 2013. Company is leveraged to secular growth in the smartphone market, Credit Suisse said. Outperform rating and new $80 price target.

Riverbed ( RVBD) estimates, target boosted at Sterne Agee. Shares now seen reaching $32. Estimates also boosted, given higher expected WAN optimization demand, Sterne Agee said. Buy rating.

Sirius XM ( SIRI) price target was boosted at Morgan Stanley to $2.40. Company is leveraged to higher U.S. auto sales, Morgan Stanley said. Equal-weight rating.

ViaSat ( VSAT) price target was raised at Oppenheimer to $59. Rollout of new broadband service is going well, Oppenheimer said. Outperform rating.

WESCO ( WCC) was added to Top Picks Live at Citigroup. $80 price target. Improving end markets and share gains, Citi said.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)